Day 1 - Exosomes Europe
- Steffen Goletz, PhD - Full Professor, Head of Biotherapeutic Glycoengineering and Immunology - Institute for Biotechnology & Biomedicine, Danish Technical University
- Bernd Giebel - Professor for Translational Extracellular Vesicle Research at University Hospital Essen and Co-Founder & CSO, Exosla Therapeutics
- Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
JAMA Therapeutics (JAMA Tx) is a preclinical-stage biotechnology company developing engineered extracellular vesicle platforms and genetic medicines for inherited cardiovascular and genetically defined neurodegenerative disorders. Its proprietary deVINCI and NEO platforms engineer extracellular vesicles for the transient, DNA-free intracellular delivery of genetic medicine. At Exosome Europe, JAMA Tx will present data on enhanced cargo loading and intracellular delivery, heart-selective delivery in vivo, and nanobody-directed targeting of engineered extracellular vesicles to the heart and brain. The company is building an internal therapeutic pipeline while advancing its scalable delivery platform technologies for co-development and strategic partnerships.
- Nazma Ilahibaks - CEO & Co-Founder, JAMA Therapeutics
- Robert Mamoun - CEO, Ciloa
- Lior Shaltiel - CEO, NurExone Biologic
- Rajeev Tawar - Associate Director, Vector and Analytical Development, Independent
Is striving for a universal EV definition delaying pipeline progression, and do regulatory agencies actually care about MISEV compliance?
Moving from rigid counting standards to bespoke analytical profiles tailored to your specific cell source and therapeutic mechanism.
How cutting-edge single-vesicle analysis, multi-omics, and advanced optical profiling bridge the gap between heterogeneity and regulatory acceptance.
What is the minimum analytical dataset required to achieve batch release without over-engineering your QC process?
- Shiran Shapira - CTO/CSO, Nano24